Filter Results:
(34)
Show Results For
- All HBS Web
(117,424)
- Faculty Publications (34)
Show Results For
- All HBS Web
(117,424)
- Faculty Publications (34)
Page 1 of 34
Results →
- September 2024
- Article
Standing on the Shoulders of Science
By: Joshua Lev Krieger, Monika Schnitzer and Martin Watzinger
Today’s innovations rely on scientific discoveries of the past, yet only some corporate
R&D builds directly on scientific output. In this paper, we analyze U.S. patents to
investigate how firms generate value by building on prior art “closer” to science. We
show... View Details
Krieger, Joshua Lev, Monika Schnitzer, and Martin Watzinger. "Standing on the Shoulders of Science." Strategic Management Journal 45, no. 9 (September 2024): 1670–1695.
- August 2024 (Revised November 2024)
- Case
Commonwealth Fusion Systems: Born at Scale
This case study chronicles the journey of Commonwealth Fusion Systems (CFS) on its ambitious mission to commercialize fusion energy and become the world’s leading provider of fusion power plants. Emerging from a “special arrangement” with MIT's Plasma Science and... View Details
Keywords: Nuclear Energy; Innovation; Energy; Innovation and Invention; Entrepreneurship; Entrepreneurial Finance; Energy Generation; Commercialization; Science
Krieger, Joshua Lev, Jim Matheson, Kyle Myers, Gunnar Trumbull, and Richard Vietor. "Commonwealth Fusion Systems: Born at Scale." Harvard Business School Case 825-061, August 2024. (Revised November 2024.)
- July 2024
- Technical Note
Intellectual Property in Tough Tech Ventures
By: Joshua Lev Krieger, Jim Matheson, Russ Wilcox and Mel Martin
Keywords: Intellectual Property
- June 2024
- Article
Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices
By: Jason Shafrin, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington and Richard Willke
This study argues that value assessment conducted from a societal perspective should rely on the Generalized Cost-Effectiveness Analysis (GCEA) framework proposed herein. Recently developed value assessment inventories—such as the Second Panel on Cost-Effectiveness’s... View Details
Shafrin, Jason, Jaehong Kim, Joshua T. Cohen, Louis P. Garrison, Dana A. Goldman, Jalpa A. Doshi, Joshua Krieger, Darius N. Lakdawalla, Peter J. Neumann, Charles E. Phelps, Melanie D. Whittington, and Richard Willke. "Valuing the Societal Impact of Medicines and Other Health Technologies: A User Guide to Current Best Practices." Forum of Health Economics and Policy 27, no. 1 (June 2024): 29–116.
- 2024
- Working Paper
Old Moats for New Models: Openness, Control, and Competition in Generative AI
By: Pierre Azoulay, Joshua L. Krieger and Abhishek Nagaraj
Drawing insights from the field of innovation economics, we discuss the likely competitive environment shaping generative AI advances. Central to our analysis are the concepts of appropriability—whether firms in the industry are able to control the knowledge generated... View Details
Azoulay, Pierre, Joshua L. Krieger, and Abhishek Nagaraj. "Old Moats for New Models: Openness, Control, and Competition in Generative AI." NBER Working Paper Series, No. 7442, May 2024.
- 2024
- Working Paper
Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency
By: Mosab Hammoudeh, Joshua Lev Krieger and Jiajie Xu
This paper investigates whether moving R&D from incumbents to startups can increase innovation. Using comprehensive drug development data, we examine the outcomes of drug projects licensed from large firms to startups. We find that these projects licensed to startups... View Details
Keywords: Product Development; Innovation and Invention; Business Startups; Research and Development; Performance Efficiency; Pharmaceutical Industry
Hammoudeh, Mosab, Joshua Lev Krieger, and Jiajie Xu. "Dusting Off the Old Ones: Drug Licensing to Startups, Innovation Success and Efficiency." Harvard Business School Working Paper, No. 24-067, March 2024.
- April 2024 (Revised August 2024)
- Case
The Engine
By: Joshua Lev Krieger, Jim Matheson, Fiona Murray and Nicholas Christman
The Engine, a venture capital firm founded by MIT to fill a gap in the technology funding landscape by commercializing breakthrough science and technology. Led by managing partner and CEO Katie Rae, the Engine's unique approach involved an unusually longer fund life,... View Details
Keywords: Growth and Development Strategy; Mission and Purpose; Venture Capital; Business Startups; Entrepreneurial Finance; Financial Services Industry
Krieger, Joshua Lev, Jim Matheson, Fiona Murray, and Nicholas Christman. "The Engine." Harvard Business School Case 824-147, April 2024. (Revised August 2024.)
- February 2024
- Supplement
Fusion Industry Association: Igniting the Future of Clean Energy
By: Kyle Myers and Joshua Lev Krieger
- February 2024
- Teaching Note
Fusion Industry Association: Igniting the Future of Clean Energy
Teaching Note for HBS Case No. 624-064. This Teaching Note explores the Fusion Industry Association's efforts to advance commercial fusion energy, highlighting challenges in innovation, regulation, market structure, and financing within the emerging technology sector... View Details
- January 2024
- Case
Fusion Industry Association: Igniting the Future of Clean Energy
Fusion energy is evolving from a scientific idea to a commercial possibility, drawing large investments and regulatory discussions; how should the FIA navigate this evolution?
The Fusion Industry Association (FIA) is at the forefront of transforming fusion... View Details
The Fusion Industry Association (FIA) is at the forefront of transforming fusion... View Details
Keywords: Science-Based Business; Engineering; Venture Capital; Entrepreneurship; Government and Politics; Government Legislation; Industry Clusters; Industry Growth; Industry Structures; Technological Innovation; Energy Industry; United States
Krieger, Joshua Lev, Jim Matheson, Kyle R. Myers, and Henry Tao. "Fusion Industry Association: Igniting the Future of Clean Energy." Harvard Business School Case 624-064, January 2024.
- 2023
- Working Paper
Evaluation and Learning in R&D Investment
By: Alexander P. Frankel, Joshua L. Krieger, Danielle Li and Dimitris Papanikolaou
We examine the role of spillover learning in shaping the value of exploratory versus incremental
R&D. Using data from drug development, we show that novel drug candidates generate more
knowledge spillovers than incremental ones. Despite being less likely to reach... View Details
Frankel, Alexander P., Joshua L. Krieger, Danielle Li, and Dimitris Papanikolaou. "Evaluation and Learning in R&D Investment." Harvard Business School Working Paper, No. 23-074, May 2023. (NBER Working Paper Series, No. 31290, May 2023.)
- September 2022
- Article
Find and Replace: R&D Investment Following the Erosion of Existing Products
By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first... View Details
Keywords: R&D Investments; Drug Development; Product Shocks; M&A; Biopharmaceutical Industry; FDA; System Shocks; Research and Development; Investment; Decision Making; Pharmaceutical Industry
Krieger, Joshua L., Xuelin Li, and Richard T. Thakor. "Find and Replace: R&D Investment Following the Erosion of Existing Products." Management Science 68, no. 9 (September 2022): 6552–6571.
- 2023
- Working Paper
Scoring and Funding Breakthrough Ideas: Evidence from a Global Pharmaceutical Company
By: Joshua Krieger, Ramana Nanda, Ian Hunt, Aimee Reynolds and Peter Tarsa
We study resource allocation to early-stage ideas at an internal startup program of
one the largest pharmaceutical firms in the world. Our research design enables us to
elicit every evaluator’s scores across five different attributes, before seeing how they
would... View Details
Keywords: Project Selection; Pharmaceuticals; Financing Innovation; Resource Allocation; Innovation and Invention; Research and Development
Krieger, Joshua, Ramana Nanda, Ian Hunt, Aimee Reynolds, and Peter Tarsa. "Scoring and Funding Breakthrough Ideas: Evidence from a Global Pharmaceutical Company." Harvard Business School Working Paper, No. 23-014, August 2022. (Revised November 2023.)
- August 2022
- Teaching Note
AppHarvest: Rebuilding the Appalachian Economy Through Agriculture
By: Joshua Lev Krieger, William R. Kerr and Bailey McAfee
- August 2022
- Teaching Note
In-Q-Tel: Innovation On A Mission
By: Josh Lerner and Joshua Lev Krieger
Teaching Note for HBS Case No. 823-031. View Details
- August 2022
- Case
In-Q-Tel: Innovation On A Mission
By: Joshua Lev Krieger and Josh Lerner
In 2022, the leaders of In-Q-Tel (IQT) considered what was next for the unique mission-driven organization. Since 1999, IQT had one mission: to be the most sophisticated source of strategic technical knowledge and capabilities to the U.S. government and its allies. IQT... View Details
Keywords: Mission and Purpose; National Security; Technological Innovation; Research; Geopolitical Units; Risk Management; Recruitment; Growth and Development Strategy; Venture Capital; Knowledge Management; Information Industry; Banking Industry
Krieger, Joshua Lev, and Josh Lerner. "In-Q-Tel: Innovation On A Mission." Harvard Business School Case 823-031, August 2022.
- March 2022
- Teaching Note
Tomorrow.io Goes To Space
By: Joshua Lev Krieger, Abhishek Nagaraj and James Barnett
Teaching Note for HBS Case No. 822-005. In March 2021, the weather company Tomorrow.io announced a new project to develop satellites equipped with radar for weather monitoring and launch them into Earth’s orbit. Company leadership considers execution strategies. View Details
- March 2022
- Teaching Note
Biobot Analytics
- 2022
- Article
Missing Novelty in Drug Development
By: Joshua Krieger, Danielle Li and Dimitris Papanikolaou
We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical innovation. We introduce a new measure of drug novelty based on chemical similarity and show that firms face a risk-reward trade-off: novel drug candidates are less likely to... View Details
Keywords: Drug Development; Risk Aversion; Research and Development; Innovation and Invention; Investment; Pharmaceutical Industry
Krieger, Joshua, Danielle Li, and Dimitris Papanikolaou. "Missing Novelty in Drug Development." Review of Financial Studies 35, no. 2 (February 2022): 636–679.
- January 2022
- Case
Tomorrow.io Goes To Space
By: Joshua Lev Krieger, Abhishek Nagaraj and James Barnett
This case study explores the evolution of Tomorrow.io, a weather forecasting technology company, as it pivoted toward building and launching space-based weather radar satellites. This strategic shift was driven by the company's ambition to overcome data limitations in... View Details
Keywords: Communication; Competency and Skills; Engineering; Globalization; Innovation and Invention; Performance; Information Technology; Aerospace Industry
Krieger, Joshua Lev, Abhishek Nagaraj, and James Barnett. "Tomorrow.io Goes To Space." Harvard Business School Case 822-005, January 2022.